In NSCLC, molecular analyses focus on actionable biomarkers associated with regulatory agency-approved therapies, including activating mutations of EGFR and BRAF and chromosomal rearrangements resulting in ALK, ROS1, and NTRK1–3 gene fusions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.